Home

 Accelerate Your Clinical Research Projects Clinical Trial Evaluation Approval Performances
Share

Approval Performances

Filters (0)
Apply filters

37-48 of 119 results

Clear filters
22776 (exPDite-2)
Parkinson’s Disease Phase III
  • 16.4 weeks
  • 1st site activated in Canada
300383 (StrateGIST 3)
Gastrointestinal Stromal Tumors (GIST) Phase III
  • 8.2 weeks
ACT18421
Chronic Rhinosinusitis Phase II
  • 9 weeks
  • Canadian FPI
ACT18421
Chronic Rhinosinusitis Phase II
  • 14.8 weeks
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
  • 6.8 weeks
  • Canadian FPI
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
  • 6.2 weeks
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
  • 7.8 weeks
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
  • 9 weeks
BN44715
Parkinson’s Disease Phase III
  • 10.4 weeks
  • 1st site activated in Canada
BN44715
Parkinson’s Disease Phase III
  • 10.6 weeks
BP41072
Lymphome Phase III
  • 14.2 weeks
C2321008
Prostate Cancer Phase III
  • 11.4 weeks
  • 1st site activated in Canada
C2321008
Prostate Cancer Phase III
  • 11.6 weeks
C2321008
Prostate Cancer Phase III
  • 11.6 weeks
C2321008
Prostate Cancer Phase III
  • 10.2 weeks
C3651021 (RIVER-mPDAC)
Cachexia and Metastatic pancreatic ductal adenocarcinoma Phase IIb/III
  • 8.4 weeks
  • 1st site activated in Canada
C3651021 (RIVER-mPDAC)
Cachexia and Metastatic pancreatic ductal adenocarcinoma Phase IIb/III
  • 8.8 weeks
C3651021 (RIVER-mPDAC)
Cachexia and Metastatic pancreatic ductal adenocarcinoma Phase IIb/III
  • 14.8 weeks
C4551002
Breast Cancer Phase III
  • 9.4 weeks
  • 1st site activated in Canada and Canadian FPI
C4551002
Breast Cancer Phase III
  • 20.6 weeks
C4551002
Breast Cancer Phase III
  • 16.6 weeks
C4551002
Breast Cancer Phase III
  • 19.6 weeks
C4921003
Heart Failure Phase II
  • 12.2 weeks
C4921003
Heart Failure Phase II
  • 12.4 weeks
C4921003
Heart Failure Phase II
  • 14.4 weeks
CA071-1000
Prostate Cancer Phase III
  • 8.8 weeks
  • 1st site activated in Canada
CA071-1000
Prostate Cancer Phase III
  • 10.6 weeks
CA071-1000
Prostate Cancer Phase III
  • 12.8 weeks
CA071-1000
Prostate Cancer Phase III
  • 10.6 weeks
  • Canadian FPI
CA240-0030
Oncology (Metastatic Pancreatic Ductal Adenocarcinoma) Phase II/III
  • 10.4 weeks
  • 1st site activated in Canada

Use the FAST TRACK Evaluation Service to Start Your Clinical Trials

Learn more Contact us